Peptide guide
Sermorelin: What the Evidence Actually Shows
Sermorelin is sold today for energy, recovery, sleep and anti-aging, and it does have a real randomized trial record — 19 controlled trials, every one of them published between 1986 and 2005. The catch is what those trials were about. They measured how much growth hormone the pituitary releases, they compared sermorelin against growth hormone in children who were not growing, and they worked out dose-response curves for a diagnostic test. Not one of them measured body fat, muscle, sleep quality or recovery in healthy adults. Sermorelin was also FDA-approved once, as Geref, and the FDA's own record now lists every Geref product as discontinued — which is why the sermorelin on sale today is compounded rather than approved.
19all 1986-2005
200521 years ago
DiscontinuedNDA019863 / NDA020443
34of 56
Compound
What it is
Sermorelin is the first 29 amino acids of growth hormone-releasing hormone, the hypothalamic signal that tells the pituitary to release growth hormone. That fragment is the shortest piece that still works, which is why it is written GHRH(1-29). It acts one step upstream of injected growth hormone: instead of supplying the hormone, it asks the pituitary to release its own, so the release stays pulsatile and stays subject to the body's own feedback. It was developed as a diagnostic agent and as a treatment for children who were short because their pituitary was not releasing enough growth hormone, and it was marketed in the United States under the brand name Geref.4,5
Mechanism
How it works
The proposed chain is short and the first link is genuinely well documented: sermorelin stimulates the pituitary, growth hormone rises, and IGF-1 rises after it. The trials measured that first link repeatedly and in detail — dose-response for low-dose bolus injections, what happens when you block the receptor, how the response compares against growth hormone-releasing peptide-2, and how age and other hormones change the size of the response. What no trial in the randomized set measured is the far end of the chain a modern seller is selling: that the extra growth hormone produces less body fat, more muscle, deeper sleep or faster recovery in a healthy adult. The mechanism is real. The outcome it is sold for was not the endpoint.1,2,3,4
Evidence
What the trials found
Evidence strength: Randomized trials. Randomized controlled trials in humans, at scale.
A PubMed search restricted to the randomized-controlled-trial publication type returns 19 records for sermorelin, and the newest was published in 2005. Read the set and it falls into three groups. The largest group is pituitary physiology: what the growth hormone response looks like after a bolus, how it interacts with clonidine, calcitonin, dopaminergic and cholinergic blockade, and how it compares with growth hormone-releasing peptide-2 and peptide-6. The second group is diagnostic dosing — a low-dose dose-response study, and work on why the response is attenuated in some groups. The third group is pediatric growth: trials comparing GHRH(1-29)-NH2 against growth hormone for stimulating growth in children with growth hormone deficiency, one of which followed quantitative growth hormone secretion through to final adult height. The most recent of the 19, from 2005, tested a polyethylene glycol-conjugated version in healthy young and elderly subjects to see whether it could be made long-acting. That is the whole randomized record.1,2,3,4,5
19
Randomized trials, 1986-2005
PubMed, randomized-controlled-trial publication type. A control search for a nonexistent peptide returns 0, so the query works.
0
Trials measuring fat, muscle or sleep
No endpoint in the randomized set is body composition, sleep quality or recovery in healthy adults.
Effect on body composition in healthy adults
Never measured in a randomized trial. Not a negative result — an absent one.
How to read the evidence meter
How to read the evidence meter
Four steps, weakest to strongest. Most peptides sold for a goal light up one. We show the step the published human evidence actually reaches — not the step the seller implies.
- AnecdotalUser reports and forum consensus. No controlled data.
- Animal onlyRodent or cell studies. Nothing published in humans.
- Early humanSmall, open-label, or phase 1/2 trials. Promising, unproven.
- Randomized trialsRandomized controlled trials in humans, at scale.
Summary
What the evidence does — and doesn't — support
What has not been studied
- Sermorelin raises growth hormone, and after it IGF-1 — measured repeatedly across the randomized set.
- It accelerated growth in children with growth hormone deficiency in trials comparing it against growth hormone.
- It works as a diagnostic agent, which is the job it was originally approved to do.
- Fat loss, lean-mass gain or body recomposition in healthy adults — not an endpoint in any of the 19 trials.
- Better sleep quality. The link is mechanistic reasoning about slow-wave sleep, not a measured outcome.
- Faster injury recovery, more energy, or slowed aging.
Show 1 more
- Any claim resting on 'FDA-approved' — the approved product, Geref, is discontinued.
Reality check
The catch
Dosing
Dosing evidence
The randomized trials used sermorelin two ways, and neither resembles a monthly wellness protocol. As a diagnostic agent it was given as a single intravenous bolus, and one of the 19 trials is explicitly a low-dose dose-response study working out how small that bolus can be and still produce an interpretable growth hormone response. As a treatment it was given to children with growth hormone deficiency as a daily subcutaneous injection over months, in trials designed to compare growth against growth hormone itself. The 2005 trial tested a PEG-conjugated form precisely because the unmodified peptide is short-acting. What the randomized record does not contain is a dose, a schedule or a duration established for a healthy adult taking sermorelin for body composition or sleep — because no randomized trial in the set enrolled that person for that purpose. This page reports what trials assigned. It does not tell any reader what to take.3,4,5
Already have a dose in mind? Our reconstitution calculator converts it to syringe units. It does not suggest one.
Safety
Safety and side effects
The randomized set is small, old, and mostly short: single-bolus physiology studies in adults and months-long dosing studies in children, which is a thin base from which to describe the safety of years of use in a healthy adult. The trials that did dose repeatedly reported endocrine and metabolic effects of long-term administration as their subject matter rather than as adverse events, and the diagnostic studies were single administrations. Two structural cautions follow from the record rather than from any adverse-event table. First, sermorelin raises growth hormone and therefore IGF-1, and the approved drug in this class carries labeled warnings about elevated IGF-1 that no compounded sermorelin label has to repeat. Second, because Geref is discontinued, a buyer is not getting the product those trials studied; they are getting a compounded preparation whose potency and sterility depend entirely on the pharmacy that made it. Anyone weighing this should be reading the compounding pharmacy's own testing, and asking their prescriber, not extrapolating safety from a 1993 pediatric trial.4
Under active FDA restriction — compliant pharmacies decline to sell it.
What the 19 trials were actually about
The number that matters is not 19. It is 2005 — the year the most recent randomized trial of sermorelin was published, twenty-one years before this page. Here is the set, grouped by what it measured.
Pituitary physiology in adults. The largest group asks how the pituitary responds. Trials measured the growth hormone response after blocking dopaminergic, adrenergic and cholinergic pathways, the interaction between clonidine and GHRH, and the effect of calcitonin on growth hormone secretion. A 1995 trial compared GHRH(1-29)NH2 against growth hormone-releasing peptide-2 in children with growth hormone insufficiency and idiopathic short stature 1. These are experiments about a signaling axis.
Diagnostic dosing. A 1994 dose-response study worked out how low a bolus can go and still produce an interpretable result, and later work examined why the response is attenuated in certain groups 3. Sermorelin's original job was as a test: give it, and see whether the pituitary answers.
Growth in children. The clinical group compared GHRH(1-29)-NH2 against growth hormone for stimulating growth in children with growth hormone deficiency, including a trial that followed quantitative growth hormone secretion through to final adult height 45. This is the closest the record comes to a treatment trial, and the population is children who were not growing.
The most recent entry, from 2005, tested whether attaching polyethylene glycol could make the peptide long-acting in healthy young and elderly subjects 2. It is a pharmacokinetics study, not an outcome trial.
Full analysis — 3 more sectionsThe approval that expired · The counting trap · What would change the picture
The approval that expired
Sermorelin is unusual among the peptides sold in this category because it genuinely was FDA-approved. Drugs@FDA lists GEREF INJECTABLE under two applications, NDA019863 and NDA020443, sponsored by EMD Serono. Every product record under both now reads Discontinued.
Two things follow that sellers rarely put side by side. A page describing sermorelin as FDA-approved is describing a drug you cannot buy, because the approved version left the market. And the sermorelin you can buy is compounded, which by definition has not been through the approval that the marketing is borrowing credibility from. Our compounding explainer covers what that distinction does and does not guarantee.
The counting trap
A ClinicalTrials.gov search for sermorelin returns 27 studies, and that number is wrong in the way that matters. Open the records and they are trials of intranasal octreotide, of VRS-317 in adults with growth hormone deficiency, and of TH9507 — which is tesamorelin, a different GHRH analog with its own approval and its own trials. They match because they mention growth hormone-releasing hormone, not because they test sermorelin.
This matters because "27 registered trials" is exactly the kind of figure that ends up in a product page. The honest statement is narrower: no interventional record names sermorelin itself as the intervention.
What would change the picture
Nothing here says sermorelin does not work for what it is sold for. It says nobody has run the trial. The study that would settle it is not exotic — randomize healthy adults to sermorelin or placebo, dose for six months, and measure fat mass, lean mass, and sleep with instruments rather than questionnaires. Until something like that is published, a seller describing sermorelin as clinically proven for energy, recovery or aging is describing trials that measured a hormone level in a different population, decades ago.
For the compound in this family that did complete modern trials, and the narrow indication it earned, see our tesamorelin page. The two records laid out row by row — what each trial measured, in whom, and which approval is still live — is on our sermorelin vs. tesamorelin comparison.
Questions
Frequently asked questions
How many clinical trials has sermorelin been in?
A PubMed search restricted to the randomized-controlled-trial publication type returns 19 records, and the most recent was published in 2005. They divide into pituitary-physiology experiments in adults, diagnostic dose-response work, and trials comparing GHRH(1-29)-NH2 against growth hormone for growth in children with growth hormone deficiency.
Is sermorelin FDA-approved?
It was, and it is not sold as an approved drug now. Drugs@FDA lists GEREF INJECTABLE under NDA019863 and NDA020443, sponsored by EMD Serono, and every product record under both applications carries the marketing status Discontinued. Sermorelin sold today is compounded, which is a different thing from the approved product.
Do the trials show sermorelin helps with weight loss or muscle?
No trial in the randomized set used body fat or lean mass as an endpoint. The 19 trials measured growth hormone secretion, the dose-response of a diagnostic bolus, and growth in children who were not growing. An absence of evidence is not proof it does nothing — it means the study has not been run.
Does sermorelin improve sleep?
Sleep quality is not an endpoint in any of the 19 randomized trials. The connection people make is mechanistic: growth hormone is secreted mostly during slow-wave sleep, so a drug that raises growth hormone is assumed to improve sleep. That is a fact about physiology, not a finding about this drug.
Why does ClinicalTrials.gov show 27 sermorelin studies?
Because the search matches text, not the intervention. Those records include trials of intranasal octreotide, VRS-317, and TH9507 — tesamorelin — which mention growth hormone-releasing hormone. No interventional record names sermorelin itself as the intervention, so 27 is not a count of sermorelin trials.
How was sermorelin dosed in the trials?
Two ways, neither of them a wellness protocol. As a diagnostic it was a single intravenous bolus, with one trial specifically working out how low that dose could go. As a treatment it was a daily subcutaneous injection given to children with growth hormone deficiency over months. No randomized trial established a dose, schedule or duration for a healthy adult taking it for body composition.
What is the difference between sermorelin and tesamorelin?
Both are GHRH analogs, and their evidence records are not comparable. Tesamorelin completed two modern phase 3 trials and holds a current FDA approval for one narrow indication, reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Sermorelin's randomized record ended in 2005 and its own approval, as Geref, is discontinued.
Glossary
Key terms
Show definitions
- GHRH(1-29)
- The first 29 amino acids of growth hormone-releasing hormone — the shortest fragment that still triggers the pituitary. It is what sermorelin is.
- Secretagogue
- A drug that makes the body release its own hormone rather than supplying the hormone directly. Sermorelin is one; injected growth hormone is not.
- Discontinued (FDA)
- The approval existed and the product is no longer marketed. It does not mean the drug was withdrawn for safety, and it does not make a compounded version approved.
Sources
References
Show all 5 sources
- Tuilpakov AN, Bulatov AA, Peterkova VA, et al. (1995). Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature. Metabolism. https://pubmed.ncbi.nlm.nih.gov/7666796/
- Munafo A, Nguyen TX, Papasouliotis O, et al. (2005). Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. European Journal of Endocrinology. https://pubmed.ncbi.nlm.nih.gov/16061831/
- Spoudeas HA, Winrow AP, Hindmarsh PC, et al. (1994). Low-dose growth hormone-releasing hormone tests: a dose-response study. European Journal of Endocrinology. https://pubmed.ncbi.nlm.nih.gov/7921207/
- Chen RG, et al. (1993). A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatrica Supplement. https://pubmed.ncbi.nlm.nih.gov/8329830/
- Neyzi O, et al. (1993). Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta Paediatrica Supplement. https://pubmed.ncbi.nlm.nih.gov/8329826/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.